Arcturus Therapeutics Stock Soars to New High Then Crashes on Trial Data – What Investors Need to Know
Arcturus stock hit a 52-week high of $24.17 on Oct. 21 before plunging up to 60% after mixed Phase 2 cystic fibrosis trial results. Interim data showed ARCT-032 was generally safe and reduced lung mucus in most patients, but failed to improve primary lung-function measures. A higher-dose cohort is underway. Analyst ratings remain moderately positive, with price targets averaging $50.
